Influence of the OPRM1 A118G polymorphism on alcohol-induced euphoria, risk for alcoholism and the clinical efficacy of naltrexone.
Alcohol-use disorders are thought to be heterogeneous in etiology, pathophysiology and response to treatment. One hypothesized contributor to this variability is the common A118G polymorphism of the µ-opioid receptor gene, OPRM1. This article critically evaluates the evidence that the A118G substitution affects subjective, behavioral and neurobiological responses to alcohol and the opioid receptor antagonist, naltrexone. Although screening of patients in a clinical setting remains premature, results suggest the A118G substitution may influence one etiological pathway to alcoholism, for which naltrexone pharmacotherapy is more effective.
Department of Neurology & Neurosurgery, McGill University, Montreal, Quebec, Canada.
Elaine
E
Setiawan
Robert O
RO
Pihl
Chawki
C
Benkelfat
Marco
M
Leyton
D000437:Alcoholism / Q000188:drug therapy* / Q000235:genetics*; D000438:Alcohols / Q000378:metabolism / Q000633:toxicity; D005059:Euphoria; D005838:Genotype; D006801:Humans; D009271:Naltrexone / Q000008:administration & dosage*; D009292:Narcotic Antagonists / Q000008:administration & dosage; D010597:Pharmacogenetics; D020641:Polymorphism, Single Nucleotide; D017450:Receptors, Opioid, mu / Q000235:genetics*
D000438:Alcohols; D009292:Narcotic Antagonists; C485764:OPRM1 protein, human; D017450:Receptors, Opioid, mu; D009271:Naltrexone